HC Wainwright Boosts Earnings Estimates for Legend Biotech

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) – Equities researchers at HC Wainwright increased their FY2025 earnings estimates for shares of Legend Biotech in a report issued on Thursday, January 22nd. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($1.32) per share for the year, up from their previous forecast of ($1.34). HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Legend Biotech’s Q4 2025 earnings at $0.12 EPS.

Legend Biotech (NASDAQ:LEGN) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. Legend Biotech had a negative return on equity of 24.47% and a negative net margin of 26.37%.The firm had revenue of $272.33 million during the quarter, compared to analyst estimates of $277.91 million. During the same quarter last year, the business posted ($0.34) earnings per share. The business’s quarterly revenue was up 70.0% compared to the same quarter last year.

LEGN has been the topic of several other reports. Jefferies Financial Group set a $21.00 price objective on Legend Biotech in a report on Thursday. Cantor Fitzgerald decreased their price target on shares of Legend Biotech from $75.00 to $74.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 17th. Raymond James Financial reiterated an “outperform” rating on shares of Legend Biotech in a research report on Tuesday, January 20th. Barclays dropped their price objective on shares of Legend Biotech from $94.00 to $90.00 and set an “overweight” rating for the company in a research note on Thursday, November 13th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Legend Biotech from $78.00 to $76.00 and set an “overweight” rating on the stock in a research report on Thursday, October 9th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $58.50.

Legend Biotech Price Performance

Shares of Legend Biotech stock opened at $19.01 on Monday. The firm has a market cap of $3.51 billion, a PE ratio of -29.25 and a beta of 0.12. The stock has a 50 day moving average of $23.93 and a 200 day moving average of $31.22. The company has a current ratio of 2.86, a quick ratio of 2.80 and a debt-to-equity ratio of 0.17. Legend Biotech has a 12 month low of $18.99 and a 12 month high of $45.30.

Institutional Investors Weigh In On Legend Biotech

Several institutional investors have recently made changes to their positions in LEGN. Clear Creek Financial Management LLC purchased a new position in shares of Legend Biotech during the 4th quarter worth about $217,000. Harbor Capital Advisors Inc. lifted its stake in Legend Biotech by 24.8% in the fourth quarter. Harbor Capital Advisors Inc. now owns 30,141 shares of the company’s stock worth $655,000 after purchasing an additional 5,996 shares during the last quarter. Aberdeen Group plc lifted its stake in Legend Biotech by 62.5% in the fourth quarter. Aberdeen Group plc now owns 29,782 shares of the company’s stock worth $647,000 after purchasing an additional 11,456 shares during the last quarter. Tempus Wealth Planning LLC boosted its position in shares of Legend Biotech by 51.3% during the fourth quarter. Tempus Wealth Planning LLC now owns 12,217 shares of the company’s stock valued at $266,000 after buying an additional 4,141 shares during the period. Finally, Banque Pictet & Cie SA bought a new position in shares of Legend Biotech during the fourth quarter valued at approximately $315,000. Institutional investors own 70.89% of the company’s stock.

About Legend Biotech

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.